EDQM suspends cert for Chinese APIs

28 April 2009

The European Directorate for the Quality of Medicines & HealthCare has suspended the Certificates of Suitability of four active pharmaceutical  ingredients manufactured in China. Two benzylpenicillin products  (R0-CEP 2004-001-Rev 00, R0-CEP 2004-017-Rev 00) from Hebei Huari  Pharmaceuticals, as well as dihydrostreptomycin sulphate (R1-CEP  2000-069-Rev 00) and neomycin sulphate (R0-CEP 2001-317-Rev 02) of  Sichuan Long March Pharmaceutical are affected.

"The EDQM auditors have obviously detected that these APIs are not  manufactured according to the submitted documentation or in line with  the requirements of ICH Q7," explained Wolfgang Heisig from the blue  inspection body GmbH. "Since the associated risk has changed, European  pharmaceutical manufacturers should now also assess those APIs  manufactured in the same premises, which have not been objected," he  added.

In mid-March, the Certificate of Suitabilty for clindamycin phosphate  from Zhejiang Pharmaceutical was suspended by the EDQM. In that  instance, the Spanish Ministry of Health had demanded the recall of 14  batches of medicinal products which contained the offending  clindamycin phosphate.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight